ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026
Factors Affecting Risk of Cardiovascular Disease (CVD) Events in a Global CVD Prevention Cohort of People With HIV.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT02344290. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Randomized Trial to Prevent Vascular Events in HIV - REPRIEVE
Who cites it
10 citing papers in PubMed.
- Hypertension Prevalence and Control at Trial Entry in the REPRIEVE Study Population: Results From a Secondary Analysis.Open forum infectious diseases · 2026Trial
- Incidence, risk factors, and cardiovascular impact of hypertension in people with HIV: a secondary analysis of the REPRIEVE trial.The lancet. HIV · 2026Trial
- Health-related quality of life among people with HIV at low-to-moderate risk for atherosclerotic cardiovascular disease in the REPRIEVE Trial.AIDS (London, England) · 2026Trial
- Primary Prevention for People Living With HIV: A Call to Action.Journal of the American College of Cardiology · 2026Article
- Sex differences in cardiovascular disease and associated factors in people living with HIV: Evidence from All of Us program.HIV medicine · 2026Article
- Prediction of Cardiovascular Risk Among People with HIV Using the PREVENT Equations Compared to the Pooled Cohort Equations.Journal of general internal medicine · 2026Observational
- Baseline ECG and Cardiovascular Outcomes in People With HIV: Insights From REPRIEVE.Journal of the American Heart Association · 2025Observational
- Cardiovascular Risk in People Living with HIV: A Preliminary Case Study from Romania.Medicina (Kaunas, Lithuania) · 2025Article
- High Burden of Cardiac Abnormalities in Adults with HIV in Ethiopia: A Multicenter Cross-Sectional Study.Journal of the International Association of Providers of AIDS CareArticle
- Global "expiration" of abacavir in adults with HIV: a rapid review of safety and efficacy concerns challenging its role in modern ART.Therapeutic advances in infectious diseaseReview
Corrections and comments
- Commented on by
Authors and funding
24 authors.
Funding
Abstract
backgroundPersons with HIV face increased risks of major adverse cardiovascular events (MACE), partially mitigated by statin therapy.
methodsWe characterized factors associated with MACE and MACE subcomponents among PWH enrolled in REPRIEVE, globally. Our primary outcome measure was time-to-first primary MACE. Secondary outcome measures included time-to-first (1) hard MACE (cardiovascular disease [CVD] death, myocardial infarction [MI], or stroke), (2) MI, or (3) stroke. For each outcome, Cox proportional hazards models were used to estimate the hazard of baseline risk factors.
resultsAmong participants (N = 7769), median age was 50 (Q1, Q3: 45, 55) years, and 31% were female. In fully adjusted models, risk of first MACE was higher for older individuals (50-59 and ≥60 vs 40-49 years; HR [95% CI]: 2.06 [1.54-2.76] and 2.53 [1.60-4.01]) and for those with Black/African-American race (vs White race, within HICs; HR: 1.65; 1.19-2.27), family history of premature CVD (HR: 1.53; 1.16-2.03), current cigarette smoking (HR: 2.27; 1.65-3.13), hypertension (HR: 1.77; 1.36-2.30), lower HDL cholesterol (HR: 1.21; 1.10-1.34), HIV-1 RNA ≥lower limit of quantification (LLQ) (HR: 1.40; 1.0-1.97), and a select antiretroviral therapy class combination (HR: 1.53; 1.01-2.31). Individuals from HICs had a higher risk of first MACE versus those from other regions, except South Asia. There was no apparent protective effect of female sex. Modeling for hard MACE, MI, and stroke yielded similar results for most variables.
conclusionsAmong PWH in REPRIEVE, select modifiable risk factors were associated with first MACE after accounting for statin effects. Female sex was not protective. CLINICAL TRIALS REGISTRATION: NCT02344290 (ClinicalTrials.gov; date of initial registration: 22 January 2015).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.